The many types of data resulting from RWE (real world evidence) provide substantial information for healthcare institutions, regulators, and pharmaceutical companies, among others, to modify their approaches. In some instances, RWE data can even mean foregoing clinical trials. Ashley Jaska and Nicolas Deltour of Aetion discuss their insights regarding RWE.
Jaska remarks, “The biggest benefit is transparency, both in terms of the data being evaluated and in the trust in the processes that transparency facilitates. Another benefit is that platforms, especially Aetion’s, provide the appropriate guardrails to help ensure good science and valid studies.” Learn more here.
(Source: Eric Mertz, Health Europa, 2/1/21)